Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

DermTech: demand to strengthen pharma partnerships over next 5 years

19-Apr-2017 - DermTech, Inc. has announced two new collaborations with pharmaceutical companies and expects more to follow as the demand for personalized, precision medicine increases.

Plasticell secures funding for red blood cell substitute development

19-Apr-2017 - Plasticell is advancing multiple projects through which it will develop and manufacture red blood cell substitutes for human clinical transfusion and progress preclinical trials.

Partnering key to deliver next-gen drug delivery tech, say industry experts

19-Apr-2017 - Partnering and collaborating to advance drug delivery innovation  is essential, now more than ever, say industry experts from Boehringer-Ingelheim and Merck.

Inoviem Scientific raises €750k, increasing lab space five-fold

18-Apr-2017 - The Contract Research Biotech (CRB) is broadening its service range as it looks to secure additional long-term deals, says CFO.

LiveLeaf contracts Emery Pharma to advance next-gen anti-infective drugs

17-Apr-2017 - LiveLeaf, Inc. has announced a collaboration with the contract research organization (CRO), Emery Pharma, to advance its development of novel prodrugs for FDA approval.

Cross-industry partnership looks to accelerate drug discovery through data sharing

13-Apr-2017 - BioCelerate has partnered with Accenture to develop a platform that will aggregate and analyze preclinical and clinical information to "drive additional industry value."

Novel in vitro approach bypasses in vivo bioequivalence studies

06-Apr-2017 - Diteba has developed a novel in vitro approach that allows sponsors to avoid in vivo bioequivalence studies in accordance with a recently released FDA draft guidance.

Envigo announces new double knockout mouse model

04-Apr-2017 - Envigo has launched a mixed-background mouse to support oncology, immuno-oncology, and infectious disease research.

Charles River launches first CRISPR-generated immunodeficient model

03-Apr-2017 - Charles River Laboratories has launched a triple-immunodeficient mouse model – a humanized mouse model, the likes of which are “the future of oncology research,” says CRO.

WuXi's LabNetwork integrates with Reaxys chemistry database

29-Mar-2017 - WuXi AppTec’s LabNetwork is collaborating with Reaxys in order to simplify customer’s purchasing decisions and expand exposure to the WuXi eCommerce platform.

Butterworth Labs aims for 60% capacity increase by 2020

29-Mar-2017 - Butterworth Laboratories Ltd has secured an additional facility in Hampton, Middlesex as it aims to increase capacity by 60% over the next three years.

Avista completes $4m facility expansion at former Microtest Labs

27-Mar-2017 - The expanded facility features an additional 4,200 square feet of space to enhance its microbiology, sterility testing, and microbial ID service offerings.

Envigo adding non-animal tech ahead of new regulations

20-Mar-2017 - Envigo is developing new In vitro tests in advance of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of the year.


Charles River to pay $1.8m to settle overbilling claims

16-Mar-2017 - The US Justice Department has announced Charles River Laboratories International Inc. will pay the US government $1.8m to settle claims that it violated the False Claims Act.

Heptares, Daiichi Sankyo to develop small molecules for pain treatment

15-Mar-2017 - Heptares Therapeutics has entered into a drug discovery and licensing agreement with Daiichi Sankyo – providing further validation of the company’s structure-based drug design approach, says CEO.

Cytel: model-informed drug development expanding area of focus

14-Mar-2017 - Cytel Inc. has established a dedicated quantitative pharmacology and pharmacometrics team to meet an increasing demand for model-informed drug development from biopharma clients.

Charles River re-ups Chiesi drug discovery contract

13-Mar-2017 - Charles River Laboratories has extended its integrated respiratory program with Chiesi Farmaceutici, through which it identifies and tests candidates for preclinical development.

SRI secures $90m BARDA contract

13-Mar-2017 - SRI International will advance compounds with the potential to treat persons exposed to biological, radiation, nuclear, and chemical agents – in a deal worth up to $90m.

News in brief

Certara expands PBPK simulator availability

09-Mar-2017 - Certara has developed a new licensing approach, which provides smaller organizations access to its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform.

CRO insourcing to gain momentum, says NovAliX

09-Mar-2017 - NovAliX has signed an insourcing agreement with UCB Biopharma, a model that the CRO says “energizes scientific organization” and offers "significant" cost advantages. 

News in brief

Cerveau tapped for Alzheimer's research

07-Mar-2017 - Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.

WuXi subsidiary HD to use Irish cell-based assays to monitor Mitochondria

06-Mar-2017 - Irish Luxcel will grant access to its consumable in vitro cell toxicity tests to Shanghai-based CRO HD Biosciences to help reduce the risk of post-market drug withdrawal.

Preclinical CRO PharmOptima joins GBG research consortium

02-Mar-2017 - Genesis Biotechnology Group (GBG) has acquired the preclinical CRO PharmOptima in order to provide customers with a single point-of-contact throughout their drug development programs.

Metrion ion channel CRO teams up with HTS specialist Assay.Works

01-Mar-2017 - Metrion has partnered with Assay.Works for an exchange of ion channels and high-throughput screening (HTS) services for drug discovery.

GBSI report outlines steps to improve preclinical research reproducibility

27-Feb-2017 - The Global Biological Standards Institute (GBSI) has outlined an action plan after finding the frequency of irreproducible preclinical research exceeds 50% – costing the US nearly $28bn.

Key Industry Events